AACR Annual Meeting 2019: Past, Present, and Future of CDK4/6-targeted Therapeutics
Therapeutics that target two proteins called cyclin-dependent kinase 4 (CDK4) and CDK6 have revolutionized treatment for breast cancer, Richard...
Category: Policy
Therapeutics that target two proteins called cyclin-dependent kinase 4 (CDK4) and CDK6 have revolutionized treatment for breast cancer, Richard...
Although checkpoint inhibitors and other immunotherapies are remarkably effective for patients with some cancers, demonstrating durable antitumor activity and/or...
“Do you want to have fun?” Richard Pazdur, MD, director of the U.S. Food and Drug Administration (FDA) Oncology...
Like many Americans, Dr. Jill Biden has been personally affected by cancer. Friends, her parents, and her son Beau...
Two of the nation’s preeminent leaders in cancer research and policy took the stage Sunday morning at the Opening...
Last Friday, March 8, 2019, marked another milestone in immuno-oncology: The U.S. Food and Drug Administration (FDA) announced the...
In the final weeks of 2018, the U.S. Food and Drug Administration (FDA) announced three approvals of anticancer therapeutics....
On September 6, 2018, the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research hosted...
The past two weeks have seen a flurry of U.S. Food and Drug Administration (FDA) approvals of new treatments...
On Monday, the U.S. Food and Drug Administration (FDA) announced the highly anticipated approval of the molecularly targeted therapeutic...